Business & Finance
Protox releases third-quarter financial results and company highlights
Published in Cancer Weekly, January 2nd, 2007
"Protox made substantial progress during the third quarter with the acquisition of PRX321 from Neurocrine Biosciences and the U.S. Public Health Service," said Dr. Fahar Merchant, president and CEO of Protox. "PRX321 significantly expands our pipeline with a Phase II clinical program that utilizes our core expertise in toxin-based targeted therapies."
Merchant added: "Approval from Health Canada for our Clinical Trial Application, received subsequent to quarter's end, allows us to initiate a Phase I human clinical trial for PRX302 to treat adult...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-01-02)
More Articles from Cancer Weekly
- Cancer Therapy
Antibody extends the life of mice with breast cancer - Cancer Therapy
Studies at cancer conference show new therapies are changing the outlook for blood cancer patients - Cancer Gene Therapy
Data on cancer gene therapy detailed by researchers at University of California - Cancer Gene Therapy
Data on cancer gene therapy published by researchers at Cornell University - Cancer Gene Therapy
Data on cancer gene therapy reported by researchers at Fudan University, Liver Cancer Institute - Cancer Gene Therapy
Investigators at West Virginia University, Mary Babb Randolph Cancer Center release new data on cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
